MetaCap

Acumen Pharmaceuticals (ABOS) vs BioStem Technologies (BSEM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioStem Technologies (BSEM) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, losing 84.0% versus a loss of 88.1%. Over five years, BSEM leads with a -55.9% price change compared with -97.7% for ABOS. Acumen Pharmaceuticals is the larger company by market cap ($13.5 million vs $12.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABOS-88.12%BSEM-83.98%
+125%+13%-98%
Nov 21, 20251 yearNov 20, 2026
ABOS-98.11%BSEM-25.28%
+2716%+1242%-232%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABOS versus BSEM key metrics
MetricABOSBSEM
Share price$0.1865$0.6351
Market cap$13.49M$12.18M
1-day change-3.52%-10.23%
YTD return-91.16%-83.33%
1-year return-88.12%-83.98%
5-year return-97.74%-55.90%
P/E ratio (TTM)—0.72
Forward P/E—2.19
EPS (TTM)$-1.55$0.88
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-121.33M—
52-week high$3.60$8.40
52-week low$0.16$0.5347
Distance from 52-week high-94.82%-92.44%
Analyst consensusstrong_buynone
Avg. price target upside+3975.07%+1002.19%
Average volume2.73M194.93K
Shares outstanding72.33M19.18M
Employees6073
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Acumen Pharmaceuticals

ABOS stock →

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees

About BioStem Technologies

BSEM stock →

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 73 employees

ABOS vs BSEM FAQ

Which is bigger, Acumen Pharmaceuticals or BioStem Technologies?

Acumen Pharmaceuticals (ABOS) is larger, with a market capitalization of $13.49M compared with $12.18M for BioStem Technologies (BSEM).

Which stock has performed better over the past year, ABOS or BSEM?

BSEM returned -83.98% over the past 12 months, compared with -88.12% for ABOS (price return, excluding dividends). Past performance does not predict future results.

Are Acumen Pharmaceuticals and BioStem Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons